Today’s exciting advances in the life sciences are allowing us to target ever more challenging and subtle interventions for a multitude of purposes. We are combating and preventing disease, feeding an ever-growing population and promoting wellbeing. At the same time our deeper understanding of risk mitigation is helping to identify potential problems and address them through both chemical and biological design.
By bringing together renowned experts in medicinal chemistry, specialist chemistry, translational biology, ADMET & DMPK, our Integrated Discovery Services division can add value to a discovery programme and enhance its probability of success.
Recent advances in synthetic methodology have created an overwhelming number of options for addressing the continuing need for new chemicals with drug-like properties. We understand the importance of knowing which methodologies will add the most value and which target molecules will progress through the rigorous scientific process to generate novel chemical entities.
When it comes to solving difficult synthetic chemistry problems, we have a unique track record that spans over 25 years and encompasses many different sectors, from pharmaceutical research to materials science, from milligrams to kilograms.
Within our specialist chemistry and medicinal chemistry groups, we have the expertise to design and create novel motifs and templates which confer new and potentially valuable properties.
Our policy is to employ large numbers of highly qualified scientists, who can add value to collaborative projects and engage in science-led peer-to-peer discussions. This not only solves problems, but also helps to drive the science to a successful outcome.
Our biology, ADMET and toxicology groups work closely with our medicinal chemists to understand the effects of a chemical on a living system. This ensures we optimise the compound’s activity by factoring the in vitro ADMET properties into its design. This helps minimise off-target effects.
As part of this process, our investigative toxicology group design and perform experiments to characterise potential (for example on-target) or observed toxicity issues. Through an understanding of mechanistic toxicology at this early research stage, we can generate information that informs molecule design, candidate selection and translational risk assessment.
Our investigative toxicology group are also acknowledged experts in the design, performance and interpretation of pre-clinical investigative and mechanistic toxicology programmes. These programmes are typically intended to identify the toxicological mode of action/adverse outcome pathway (AOP) affected by the compound in question. Our experience spans the pharmaceutical, agrochemical, chemical and consumer products industries and the mechanistic data we generate is frequently used in submissions to regulators.
Explore the service areas below to find out more:
Concept Life Sciences' expertise in medicinal chemistry spans numerous therapeutic areas, taking the drug discovery...
We work with clients from target identification through to candidate selection and pre-clinical support. Target...
ADMET & DMPK
Our in vitro and in vivo ADMET & DMPK services include in vitro and in vivo...
Concept Life Sciences has an extensive track record in the design, performance and interpretation of pre-clinical...
Concept Life Sciences is a leading provider of synthetic chemistry services. Our expertise extends to chiral synthesis,...
Specialist chemistry services
Concept Life Sciences has had notable success in several specialist chemistry disciplines. Our expertise covers...